Codiak BioSciences is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics. Founded in 2015 and based in the Boston area, the company has been involved in developing innovative treatments using exosomes. However, in 2023, Codiak BioSciences filed for Chapter 11 bankruptcy as it struggled to meet its financial obligations.
Focus Areas
Notable Investments
